When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BOLD - Audentes gene therapy for rare neuromuscular disorder shows positive action in study
Audentes Therapeutics Inc.
Updated data from a Phase 1/2 clinical trial, ASPIRO, evaluating Audentes Therapeutics' (BOLD-0.6%) gene therapy candidate AT132 in patients with X-linked myotubular myopathy (XLMTM) showed a treatment effect. The results were presented at the American Society of Gene and Cell Therapy Annual Meeting in Washington, DC.
More news on: Audentes Therapeutics, Inc., Healthcare stocks news,